Quantitative evaluation of the effect of the hepatitis B vaccine based on the HBsAg- and anti-HBs-positive rates in the Chinese population over the last 33 years

Vaccine

Volumn 30, Issue 23, 2012, Pages 3483-3487

  Liu, Hui ^a   Ma, Yonglei ^a   Wang, Hongfei ^a   Liu, Qigui ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Anti HBs; HBsAg; Hepatitis B; Vaccine

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ARTICLE; CHINESE; CLINICAL EVALUATION; DRUG EFFECT; HEPATITIS B; HUMAN; LABORATORY DIAGNOSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHINA; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 84859829437     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.053     Document Type: Article

References (14)

1. Zou L., Zhang W., Ruan S. Modeling the transmission dynamics and control of hepatitis B virus in China. J Theor Biol 2010, 262(2):330-338.
2. Poorolajal J., Mahmoodi M., Majdzadeh R., Nasseri-Moghaddam S., Haghdoost A., Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 2010, 28(3):623-631.
3. Sanyal G., Shi L. A review of multiple approaches towards an improved hepatitis B vaccine. Expert Opin Ther Pat 2009, 19(1):59-72.
4. Luo Z., Xie Y., Deng M., Zhou X., Ruan B. Prevalence of hepatitis B in the southeast of China: a population-based study with a large sample size. Eur J Gastroenterol Hepatol 2011, 23(8):695-700.
5. Zhang H., Li Q., Sun J., Wang C., Gu Q., Feng X., et al. Seroprevalence and risk factors for hepatitis B infection in an adult population in Northeast China. Int J Med Sci 2011, 8(4):321-331.
6. Lu F.M., Zhuang H. Prevention of hepatitis B in China: achievements and challenges. Chin Med J (Engl) 2009, 122(24):2925-2927.
7. Zhou Y.H., Wu C., Zhuang H. Vaccination against hepatitis B: the Chinese experience. Chin Med J (Engl) 2009, 122(1):98-102.
8. Ministry of Health of the People's Republic of China Year book of public health in the People's Republic of China in 2009 2009, Peking Union Medical College Press, pp. 23-283.
9. Huang C.F., Lin S.S., Ho Y.C., Chen F.L., Yang C.C. The immune response induced by hepatitis B virus principal antigens. Cell Mol Immunol 2006, 3(2):97-106.
10. Chen C.C., Yen C.H., Wu W.Y., Hu S.W., Chen S.C., Bell W.R., et al. Epidemiology of hepatitis B virus infection among young adults in Taiwan, China after public vaccination program. Chin Med J (Engl) 2007, 120(13):1155-1158.
11. Odusanya O.O., Alufohai E., Meurice F.P., Ahonkhai V.I. Five-year post vaccination efficacy of hepatitis B vaccine in rural Nigeria. Hum Vaccin 2011, 7(6):625-629.
12. La Torre G., Nicolotti N., de Waure C., Chiaradia G., Specchia M.L., Mannocci A., et al. An assessment of the effect of hepatitis B vaccine in decreasing the amount of hepatitis B disease in Italy. Virol J 2008, 5:84.
13. Shao Z.J., Zhang L., Xu J.Q., Xu D.Z., Men K., Zhang J.X., et al. Mother-to-infant transmission of hepatitis B virus: a Chinese experience. J Med Virol 2011, 83(5):791-795.
14. Merrill R.M., Hunter B.D. Seroprevalence of markers for hepatitis B viral infection. Int J Infect Dis 2011, 15(2):e78-e121.